A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-30. Anything still debated is marked as such rather than presented as settled.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== External links == Kavkaz-2008 leaflet ("Soldier, know your probable enemy"), The Guns of August 2008: Russia's War in Georgia, p. xi - xii Anna Nemtsova, Q&A: Georgia's Mikheil Saakashvili on Russia Fight, Newsweek, 11 August 2008 William Rees-Mogg, Georgia: another Sarajevo moment avoided, The Times, 11 August 2008 Illarionov: Russia Lost the Georgian War, The Other Russia, 13 August 2008 (in Russian) "We Will never surrender", Der Spiegel, 18 August 2008 (in Russian) Vadim Rechakolv's comment on the movement of Russian tank column through the Roki Tunnel on 7 August Denis Macshane, Denis MacShane Explores the Myths About Russia, Newsweek, 5 September 2008 Ministry of Foreign Affairs of Georgia, Media and telephone intercepts confirm Russia started the war, 20 September 2008 (in Russian) André Glucksmann, Putin's doctrine, 22 October 2008 The Government of Georgia, Factual Evidence Contradicts War Claims in Recent Media Stories;, 18 November 2008 Bear on the Prowl? The Return of Russia as a Great Power Archived 17 March 2024 at the Wayback Machine; Australian Institute of International Affairs, November 2008 Julia Latynina - Articles on August war (Translations) Report by the Government of Georgia on the aggression by the Russian Federation against Georgia, 7 August 2009. PDF file. (in Russian) Grani TV, Andrei Nekrasov, Movie director, Garry Kasparov about "Russian Lessons", 14 September 2009 Caucasus Analytical Digest No.
Clot formation: Once the platelet plug has been formed by the platelets, the clotting factors (a dozen proteins that travel along the blood plasma in an inactive state) are activated in a sequence of events known as 'coagulation cascade' which leads to the formation of fibrin from inactive fibrinogen plasma protein. Thus, a fibrin mesh is produced all around the platelet plug to hold it in place; this step is called secondary hemostasis. During this process some red and white blood cells are trapped in the mesh which causes the primary hemostasis plug to become harder: the resultant plug is called a thrombus or blood clot. The blood clot contains the secondary hemostasis plug with blood cells trapped in it. This is a necessary step for wound healing, but it has the ability to cause severe health problems if the thrombus becomes detached from the vessel wall and travels through the circulatory system; If it reaches the brain, heart or lungs it could lead to stroke, heart attack, or pulmonary embolism respectively.
=== Early career (1986–1991) === Steve Austin began his wrestling training in 1986 under Chris Adams at the Dallas Sportatorium, when Adams was affiliated with World Class Wrestling Association (WCWA, formerly WCCW). Although the training emphasized technical skills, Austin later expressed dissatisfaction with the lack of instruction on the business side of wrestling. Austin made his in-ring debut later that year in a televised WCWA match using his real name at the time, Steve Williams. During the merger of WCWA and the Memphis-based Continental Wrestling Association into the United States Wrestling Association (USWA), he began wrestling under the name "Steve Austin", a change made to avoid confusion with "Dr. Death" Steve Williams. He competed primarily in Dallas and was managed by Percy Pringle (later known as Paul Bearer in WWF) during this period. One of his early storylines involved a feud with his trainer, Chris Adams.
Sources: en.wikipedia.org
Although some medical authorities recommend mirroring the terminology transgender people use to describe their own genitals, such usage may feel uncomfortable and intimate to some transgender people, who prefer to use different terms in medical contexts than they would in personal settings. At the same time, patients may also be uncomfortable with anatomical terms they perceive as gendered. Specialists recommend being open to using sex-neutral terms for organs, such as external genitals or lateral folds for the labia, internal reproductive organs for the uterus and ovaries, and chest for the breasts. Style guides such as the Publication Manual of the American Psychological Association and AMA Manual of Style recommend using gender-neutral language and distinguishing between gender and biological sex, but do not give guidance on specific anatomical terminology.
== Contamination sources and removal == Bacteria, particles, organic carbon, ions, and dissolved gases are all present in typical municipal water systems and must be removed to create ultrapure water.
It was, unlike the first film, a true representation of Judge Dredd ... Karl Urban was a fine Dredd and I'd be more than happy to see him in the follow-up. Olivia Thirlby excelled as Anderson ... The character and storyline are pure Dredd." Dredd has been recognised as a cult film since its release. Some reviewers drew comparisons between Dredd and The Raid: Redemption, another action film released a few months earlier, noting that similar elements in setting, story, and characters made Dredd appear derivative. However, Garland and Urban explained that the timing of when the films were shot would have made plagiarism impossible.
Sources: en.wikipedia.org
==== Serotonin–norepinephrine reuptake inhibitors (SNRIs) ==== Duloxetine (Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve) – serotonin–norepinephrine reuptake inhibitor (SNRI) [40] Venlafaxine (Dobupal; Efexor XR; Effexor; Effexor XR; Elafax; WY-45030; WY-45651; WY-45655) – serotonin–norepinephrine reuptake inhibitor (SNRI) [41]
=== Hyperrelaxinemia === Premature delivery of relaxin is linked to high levels of relaxin in the mother's bloodstream, known as hyperrelaxinemia. This is caused by the impact of relaxin on the cervix, which disrupts the equilibrium in maintaining the structure of cervical connective tissue. Hyperrelaxinemia caused by ovarian stimulation results in an increased rate of the risk of premature labor and preterm birth.
Among numerous advances in experimental techniques he has developed experimental methods for using DNA microarrays to investigate the basic principles of genome organization. Member Natl. Acad. Sci. USA. Thomas Bruice (1925–2019). American bioorganic chemist at UC Santa Barbara, pioneering researcher in chemical biology. Member Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.